Desmopressin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Desmopressin
- Desmopressin: From von Willebrand Disease and Nocturnal Enuresis to Congenital Prothrombin Deficiency
Desmopressin: From von Willebrand Disease and Nocturnal Enuresis to Congenital Prothrombin Deficiency
One-Sentence Summary
Desmopressin was originally used for hereditary von Willebrand disease, haemophilia (including symptomatic female carriers) and nocturnal enuresis. The TxGNN model predicts it may be effective for congenital prothrombin deficiency, but the top-ranked prediction has no clinical trials and only 1 publication (a 1993 general review), so the supporting evidence is very weak. Among the top 10 predictions, only primary release disorder of platelets has meaningful supporting data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hereditary von Willebrand disease, haemophilia, nocturnal enuresis (the approved indication text for Singapore licences was not available) |
| Predicted New Indication | Congenital prothrombin deficiency (rank 1) |
| TxGNN Prediction Score | 99.70% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, desmopressin is a synthetic vasopressin analogue. It raises plasma von Willebrand factor (VWF) and factor VIII through V2 receptor-mediated release from the endothelium. Its efficacy in von Willebrand disease and mild haemophilia A is established.
For the top-ranked prediction, congenital prothrombin deficiency, the mechanistic link is weak. Desmopressin has no known direct effect on prothrombin (factor II) levels. The high TxGNN score most likely reflects network proximity to other bleeding disorders rather than a true pharmacological relationship. The only literature is a 1993 general review of congenital bleeding disorders.
Looking across the ten predictions, the picture is mixed:
- Most plausible: primary release disorder of platelets (storage pool and aspirin-like defects). Desmopressin can shorten bleeding time by enhancing platelet-vessel wall interaction, and a paediatric study and a 2023 review support this.
- Indirect or uncertain: Glanzmann thrombasthenia (adjunct at best), bleeding diathesis due to a collagen receptor defect.
- Likely harmful (false-positive signals): thrombotic thrombocytopenic purpura, platelet-type (pseudo-) von Willebrand disease and inherited thrombophilia. Desmopressin releases VWF and may worsen these conditions.
- No supporting basis: Scott syndrome, hereditary thrombocytosis with transverse limb defect, and "flood factor deficiency" (likely an ontology mapping artefact).
Clinical Trial Evidence
Currently no related clinical trials registered for the top-ranked prediction or for any of the other nine predictions reviewed.
Literature Evidence
Literature for the rank-1 prediction (congenital prothrombin deficiency):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7684674 | 1993 | Review | Drugs | General review of treatment options for inherited bleeding disorders; no specific data on desmopressin in prothrombin deficiency |
Most relevant literature across the other predictions:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36656570 | 2023 | Review | Eur J Haematol | Desmopressin releases VWF and FVIII and shortens bleeding time; useful in mild haemophilia A, certain VWD subtypes, uraemic and liver-disease bleeding; risks include hyponatraemia and rare arterial thrombosis |
| 21509710 | 2011 | Cohort | Klin Padiatr | Desmopressin effect on primary haemostasis in children with aspirin-like platelet defect |
| 23051555 | 2013 | Mechanistic study | Haemophilia | After desmopressin infusion, more VWF is bound to microparticles, which may explain effects in platelet disorders |
| 10509036 | 1999 | Study | Haematologica | In vitro and in vivo effects of desmopressin on platelet function |
| 1785670 | 1991 | Clinical study | Am J Pediatr Hematol Oncol | Desmopressin plus ethamsylate shortened bleeding time in 12 patients with various bleeding disorders unresponsive to desmopressin alone |
| 16444446 | 2006 | Case report | Clin Appl Thromb Hemost | Glanzmann thrombasthenia: desmopressin was ineffective, and recombinant factor VIIa achieved haemostasis for dental extraction |
| 21921792 | 2011 | Case report | Blood Coagul Fibrinolysis | Moschcowitz-like (TTP-like) syndrome after desmopressin for postpartum haemorrhage |
| 15499705 | 2004 | Case report | Thromb Haemost | Worsening of TTP symptoms associated with desmopressin |
| 16460464 | 2006 | Case report | J Thromb Haemost | Link between desmopressin use for enuresis and inherited TTP (Upshaw-Schulman syndrome) |
| 12109311 | 2002 | Case report | Ned Tijdschr Geneeskd | A trial dose of desmopressin led to severe thrombocytopenia in a patient with von Willebrand disease type 2 (later identified as type 2B) |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15461P | NOCDURNA Oral Lyophilisate 25 mcg | Orally disintegrating tablet | Not available |
| SIN15462P | NOCDURNA Oral Lyophilisate 50 mcg | Orally disintegrating tablet | Not available |
| SIN14261P | MINIRIN Oral Lyophilisate 120 mcg | Orally disintegrating tablet | Not available |
| SIN14260P | MINIRIN Oral Lyophilisate 60 mcg | Orally disintegrating tablet | Not available |
| SIN11656P | MINIRIN Tablet 0.1 mg (Oval) | Tablet | Not available |
Two further licences are valid: MINIRIN Nasal Spray 10 mcg/dose (SIN03760P, spray) and MINIRIN Injection 4 mcg/ml (SIN04482P, injection). All seven registrations are single-ingredient products. Oral, nasal and injectable routes are therefore all available in Singapore.
Safety Considerations
- Contraindications and warnings from the knowledge graph (not label text): the TxGNN knowledge graph flags the following conditions: hypertension, coronary artery disease, impaired renal function, allergic and vasomotor rhinitis, pharyngitis, common cold, respiratory tract infection, cystic fibrosis, polydipsia (including dipsogenic diabetes insipidus), water intoxication, and von Willebrand disease (likely specific subtypes such as type 2B).
- Predicted-indication safety signals: case reports describe desmopressin-induced or worsened TTP and thrombocytopenia in VWD type 2B. A 2023 review also notes hyponatraemia and rare arterial thrombotic events.
- Drug interactions: 100 interactions were identified. Those rated Major are systemic and inhaled corticosteroids (hydrocortisone, dexamethasone, prednisolone, prednisone, triamcinolone, betamethasone, budesonide, beclomethasone). Moderate interactions include epinephrine, loperamide, morphine, opium and chlorpropamide. Aspirin is rated Minor.
Please refer to the package insert for the full official warnings and contraindications, which were not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (congenital prothrombin deficiency) has no clinical trials, only one general review and no plausible mechanism, so its high score looks like a network artefact. Among the ten predictions, only primary release disorder of platelets has supportive evidence (L3, small observational and physiological studies), which merits "Proceed with Guardrails" as a separate, narrower candidate. Several other predictions (TTP, platelet-type VWD, inherited thrombophilia) represent safety risks, not benefits.
To proceed, the following is needed:
- Redirect evaluation toward primary release disorder of platelets: prospective studies or a structured desmopressin trial test, with sodium and fluid monitoring and caution in patients at thrombotic risk
- Mechanism of action data (DrugBank)
- HSA package insert warnings, contraindications and approved indication text, which are required before any safety screening
- Ontology verification of "flood factor deficiency" and other questionable disease terms
- Explicit exclusion of TTP, platelet-type VWD and inherited thrombophilia from any repurposing pipeline on safety grounds
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.